Yüklüyor......
A Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 1β3) in Patients With Systolic Dysfunction and Heart Failure
A first-in-human, phase 1, double blind, placebo-controlled, single ascending dose study examined the safety, tolerability, and exploratory efficacy of intravenous infusion of a recombinant growth factor, cimaglermin alfa, in patients with heart failure and left ventricular systolic dysfunction (LVS...
Kaydedildi:
| Yayımlandı: | JACC Basic Transl Sci |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Elsevier
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6113538/ https://ncbi.nlm.nih.gov/pubmed/30167542 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jacbts.2016.09.005 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|